GoAI
Get started
Mizuho Medy Co.,Ltd. logo

Mizuho Medy Co.,Ltd.

4595.T

JPXHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

¥1,735

+¥14.00 · +0.81%

Aug 24, 2:32 PM JSTData delayed

4595.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
JP
CEO
Fuminari Karakawa
Listed since
Dec 18, 2015
Employees
193

Market position

Day range

Current ¥1,735

52-week range

Current ¥1,735

Open
¥1,723
Previous close
¥1,721
Volume
74.5K
0.76× average
Average volume
98.48K
Average daily volume
Market cap
33.05B JPY
Beta
0.52
Market reference 1
50-day average
¥1,676.22
+3.51% above average
200-day average
¥1,735
at average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
21.65B JPY
P/E (TTM)
10.24×
P/B (TTM)
1.78×
P/S (TTM)
3.06×
EV / EBITDA
4.41×
Earnings yield
10.55%
Free cash flow yield
5.24%
Dividend yield
5.76%

Profitability & efficiency

Gross margin
68.40%
Operating margin
38.53%
Net margin
29.83%
Return on equity
18.33%
Return on assets
15.31%
Return on invested capital
17.05%

Financial health

Debt / equity
0×
Current ratio
7.36×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends85%65%45%25%Gross margin, FY2021: 74.55%Gross margin, FY2022: 79.90%Gross margin, FY2023: 73.03%Gross margin, FY2024: 70.34%Gross margin, FY2025: 69.07%Operating margin, FY2021: 51.98%Operating margin, FY2022: 63.16%Operating margin, FY2023: 46.88%Operating margin, FY2024: 43.03%Operating margin, FY2025: 41.27%Net margin, FY2021: 37.38%Net margin, FY2022: 44.58%Net margin, FY2023: 34.34%Net margin, FY2024: 33.01%Net margin, FY2025: 30.42%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 74.55%. Gross margin FY2022 79.90%. Gross margin FY2023 73.03%. Gross margin FY2024 70.34%. Gross margin FY2025 69.07%. Operating margin FY2021 51.98%. Operating margin FY2022 63.16%. Operating margin FY2023 46.88%. Operating margin FY2024 43.03%. Operating margin FY2025 41.27%. Net margin FY2021 37.38%. Net margin FY2022 44.58%. Net margin FY2023 34.34%. Net margin FY2024 33.01%. Net margin FY2025 30.42%.

Income trends

Revenue

11.26B JPY-1.48%

Operating income

4.65B JPY-5.51%

Net income

3.43B JPY-9.22%
Income trends across reported periods19B JPY13.33B JPY7.67B JPY2.01B JPYRevenue, FY2021: 12.89B JPYRevenue, FY2022: 17.58B JPYRevenue, FY2023: 10.99B JPYRevenue, FY2024: 11.43B JPYRevenue, FY2025: 11.26B JPYOperating income, FY2021: 6.7B JPYOperating income, FY2022: 11.1B JPYOperating income, FY2023: 5.15B JPYOperating income, FY2024: 4.92B JPYOperating income, FY2025: 4.65B JPYNet income, FY2021: 4.82B JPYNet income, FY2022: 7.84B JPYNet income, FY2023: 3.77B JPYNet income, FY2024: 3.77B JPYNet income, FY2025: 3.43B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12.89B JPY. Revenue FY2022 17.58B JPY. Revenue FY2023 10.99B JPY. Revenue FY2024 11.43B JPY. Revenue FY2025 11.26B JPY. Operating income FY2021 6.7B JPY. Operating income FY2022 11.1B JPY. Operating income FY2023 5.15B JPY. Operating income FY2024 4.92B JPY. Operating income FY2025 4.65B JPY. Net income FY2021 4.82B JPY. Net income FY2022 7.84B JPY. Net income FY2023 3.77B JPY. Net income FY2024 3.77B JPY. Net income FY2025 3.43B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue11.26B JPY11.43B JPY10.99B JPY17.58B JPY12.89B JPY
Cost of goods sold3.48B JPY3.39B JPY2.96B JPY3.53B JPY3.28B JPY
Gross profit7.78B JPY8.04B JPY8.03B JPY14.05B JPY9.61B JPY
Research and development819M JPY783M JPY669.08M JPY605.47M JPY592.32M JPY
Selling, general, and administrative2.31B JPY2.34B JPY2.2B JPY2.34B JPY2.32B JPY
Operating expenses3.13B JPY3.12B JPY2.87B JPY2.94B JPY2.91B JPY
Interest income100M JPY75M JPY41.44M JPY9.47M JPY1.77M JPY
Interest expense————1.24M JPY
Depreciation and amortization266M JPY186M JPY243.82M JPY157.78M JPY172.6M JPY
Operating income4.65B JPY4.92B JPY5.15B JPY11.1B JPY6.7B JPY
Net income3.43B JPY3.77B JPY3.77B JPY7.84B JPY4.82B JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
11.61

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates103.272.0940.989.87Q4 '24Q1 '25Q2 '25Q3 '25Q3 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 8, 2024: actual 55.7, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 7, 2025: actual 64.2, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 9, 2025: actual 40.79, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 7, 2025: actual 12.76, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual 29.82, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual 96.42, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual 31.57, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 12, 2026: actual 11.61, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.43B3.99B2.56B1.13BQ1 '25BeatQ2 '25BeatQ3 '25MissQ3 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 7, 2025: actual 3.44B JPY, estimate 2.59B JPY, surprise +32.82%, Beat. Q2 2025, reported May 9, 2025: actual 2.65B JPY, estimate 2.6B JPY, surprise +1.88%, Beat. Q3 2025, reported Aug 7, 2025: actual 1.33B JPY, estimate 3.2B JPY, surprise -58.53%, Miss. Q3 2025, reported Sep 30, 2025: actual 2.25B JPY, estimate 2.32B JPY, surprise -3.18%, Miss. Q1 2026, reported Feb 13, 2026: actual 5.03B JPY, estimate 5.12B JPY, surprise -1.76%, Miss. Q2 2026, reported May 13, 2026: actual 2.21B JPY, estimate 3B JPY, surprise -26.40%, Miss. Q3 2026, reported Aug 12, 2026: actual 1.33B JPY, estimate 1.49B JPY, surprise -11.19%, Miss. Q4 2026, reported Nov 6, 2026: actual —, estimate 2.3B JPY, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

¥100

2025 complete year+29.0% since 2021

2026 partial: ¥50.00

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Dec 29, 2026

¥50.00

Semi-Annual

Record Dec 31, 2026 · Payment Dec 29, 2026

Dividend

Ex-dividend Jun 29, 2026

¥50.00

Semi-Annual

Record Jun 30, 2026 · Payment Sep 11, 2026

Dividend

Ex-dividend Dec 29, 2025

¥50.00

Semi-Annual

Record Dec 31, 2025 · Payment Mar 30, 2026

Dividend

Ex-dividend Jun 27, 2025

¥50.00

Semi-Annual

Record Jun 30, 2025 · Payment Sep 11, 2025

Dividend

Ex-dividend Jun 27, 2024

¥80.00

Annual

Record Jun 30, 2024 · Payment Sep 11, 2024

Dividend

Ex-dividend Dec 28, 2023

¥140

Special

Record Dec 31, 2023 · Payment Mar 29, 2024

4595.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,989

-0.31%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,817

+0.92%

HOYA Corporation logo

7741.T

HOYA Corporation

¥25,030

+0.54%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,280

+0.70%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,866.5

+1.16%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,405

+0.75%

ETFs holding 4595.T

Funds reporting this stock among their holdings, ordered by reported position size.

WisdomTree Dynamic International Equity Fund logoWisdomTree Dynamic International Equity FundDDWM
Market value
481.14K
Weight
0.04%
AUM
1.49B USD
Expense ratio
0.40%
Price / 1D
$47.395+0.65%
iShares International Small-Cap Equity Factor ETF logoiShares International Small-Cap Equity Factor ETFISCF
Market value
470.01K
Weight
0.07%
AUM
684.58M USD
Expense ratio
0.24%
Price / 1D
$46.03+0.81%
Dimensional - International Core Equity 2 ETF logoDimensional - International Core Equity 2 ETFDFIC
Market value
266.27K
Weight
0.00%
AUM
15.43B USD
Expense ratio
0.22%
Price / 1D
$39.405+0.83%
Dimensional - International Small Cap ETF logoDimensional - International Small Cap ETFDFIS
Market value
251.17K
Weight
0.00%
AUM
5.91B USD
Expense ratio
0.39%
Price / 1D
$37.545+0.71%
Dimensional - International Core Equity Market ETF logoDimensional - International Core Equity Market ETFDFAI
Market value
189.73K
Weight
0.00%
AUM
18.23B USD
Expense ratio
0.18%
Price / 1D
$43.35+0.81%
WisdomTree Japan SmallCap Dividend Fund logoWisdomTree Japan SmallCap Dividend FundDFJ
Market value
167.39K
Weight
0.04%
AUM
388.69M USD
Expense ratio
0.58%
Price / 1D
$113.06+0.82%
WisdomTree Dynamic International SmallCap Equity ETF logoWisdomTree Dynamic International SmallCap Equity ETFDDLS
Market value
131.52K
Weight
0.03%
AUM
423.98M USD
Expense ratio
0.48%
Price / 1D
$45.945+0.47%
Dimensional World ex U.S. Core Equity 2 ETF logoDimensional World ex U.S. Core Equity 2 ETFDFAX
Market value
125.05K
Weight
0.00%
AUM
12.57B USD
Expense ratio
0.28%
Price / 1D
$38.16+0.82%

Continue in GoAI

Research 4595.T

research.disclaimer